Success Metrics

Clinical Success Rate
93.9%

Based on 46 completed trials

Completion Rate
94%(46/49)
Active Trials
0(0%)
Results Posted
93%(43 trials)
Terminated
3(6%)

Phase Distribution

Ph phase_2
24
49%
Ph phase_3
24
49%

Phase Distribution

0

Early Stage

24

Mid Stage

24

Late Stage

Phase Distribution48 total trials
Phase 2Efficacy & side effects
24(50.0%)
Phase 3Large-scale testing
24(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

93.9%

46 of 49 finished

Non-Completion Rate

6.1%

3 ended early

Currently Active

0

trials recruiting

Total Trials

49

all time

Status Distribution
Completed(46)
Terminated(3)

Detailed Status

Completed46
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
49
Active
0
Success Rate
93.9%
Most Advanced
Phase 3

Trials by Phase

Phase 224 (50.0%)
Phase 324 (50.0%)

Trials by Status

terminated36%
completed4694%

Recent Activity

Clinical Trials (49)

Showing 20 of 49 trialsScroll for more
NCT01440595Phase 2

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Terminated
NCT02219490Phase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT02167945Phase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT01482767Phase 3

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Completed
NCT02194998Phase 2

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Terminated
NCT00991289Phase 2

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Completed
NCT02455167Phase 3

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

Terminated
NCT02243293Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Completed
NCT01685203Phase 2

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

Completed
NCT02723084Phase 3

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

Completed
NCT02292719Phase 2

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Completed
NCT01995071Phase 2

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Completed
NCT01704755Phase 3

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Completed
NCT01023035Phase 3

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Completed
NCT02332720Phase 2

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

Completed
NCT00704405Phase 2

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Completed
NCT02105454Phase 2

Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

Completed
NCT01390844Phase 3

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Completed
NCT03020004Phase 2

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Completed
NCT01314261Phase 2

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Completed

Drug Details

Intervention Type
DRUG
Total Trials
49